CareDx
CareDx Preliminary Q4 Revenues up 4 Percent
The company says that strong test growth, cash collection, and guidelines inclusion helped drive fourth quarter revenues of $81.9 million to $82.2 million.
CareDx to Repurchase up to $50M of Common Stock
The company plans to purchase common shares through open market, privately negotiated, or other means for up to 24 months.
360Dx Top 30 Grows 8 Percent, Continues Upward Climb
Of the 30 companies in the index, 21 saw their stock prices rise, while nine firms' share prices decreased.
CareDx Q3 Revenues Grow 5 Percent, Miss Analyst Estimates
Testing services revenue drove a 5 percent year-over-year increase, with AlloMap Kidney under MolDX review.
CareDx Q2 Revenues Grow 9 Percent but Miss Estimates as Firm Lowers Full-Year Guidance
Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year.
May 5, 2022
CareDx Q1 Revenues up 18 Percent
Apr 20, 2022
Feb 24, 2022
CareDx Q4 Revenues Rise 35 Percent
Oct 29, 2021